| [1] |
CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun.
48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798.
|
| [2] |
FU Weiran, ZOU Dongmei, NI Jing, SUN Wanling, GUO Yixian.
Short-Term Efficacy and Safety of Thiotepia-based Conditioning Regimen Combined with Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Primary Central Nervous System Lymphoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 664-668.
|
| [3] |
ZHENG Kaifan, LENG Hongxu, XU Kaixuan, CAI Wenlu, ZHANG Ying, ZHAO Pengfei, TAN Shengjie, XIN Guizhong.
Research Progress on Intestinal Safety of Anthraquinone Laxatives
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 708-713.
|
| [4] |
XIE Ziyue, WANG Chengxiang, HU Yanpeng, LI Lei, CUI Herong.
Clinical Medications and Safety Analysis of Traditional Chinese Medicine for Post-Infection Cough
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 507-512.
|
| [5] |
WANG Han, WANG Cunxuan, LYU Xuehaiyue, ZHANG Lining, SUO Yusi, GU Zhi'en, WANG Ping, JIN Xuejing.
Chinese Patent Medicines for Preventing Myelosuppression in Adjuvant Treatment of Malignant Tumors: a Systematic Review and Network Meta-Analysis
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 169-176.
|
| [6] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|
| [7] |
WANG Yuxi, ZHANG Zonglin, WANG Yingli, CHEN Yafei, LI Junsheng, HUO Yanfei, XIE Yanjun, LIU Wenqi.
560 cases of adverse drug reaction/event caused by Mailu Shutong pills
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 921-924.
|
| [8] |
ZHAO Jun, DONG li, WANG Yang, LIANG Yu, YANG Xue, LI Enze.
Adverse reaction/event reports of esmolol
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 925-930.
|
| [9] |
LIU Yan, AN Jing, JIAO Yongzhuo, LIANG Xuefeng, ZHANG Xiaoshu.
Simple febrile seizures within 30 days of vaccination with the measles, mumps and rubella combined attenuated live vaccine in U-12 children in the real world
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 805-810.
|
| [10] |
ZHAO Xuan, ZHENG Tingting, LI Xuemei, MAO Lu, GUO Jing, ZHANG Wei.
Adverse reaction reports of vancomycin in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 811-815.
|
| [11] |
SUN Xuelin, DU Jiao, TAN Qin, HU Xin, ZHANG Yatong, ZHENG Li.
Analysis of post-marketing adverse reactions of ametinib
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 683-686.
|
| [12] |
LIU Tianrui, LI Yao, CHEN Yuxin, LI Hui, GAO Haiyun, YUAN Yuan.
Toxicity analysis and safe application of 7 common fungi prone to adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 489-495.
|
| [13] |
SU Xiaohan, ZENG Jiao, LI Xue, LIU Lixin, HOU Lingmi, LI Jinsui.
Adverse events of abemaciclib in breast cancer patients based on US FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 580-586.
|
| [14] |
LIU Qi, ZHANG Yufeng, LUO Hao, LI Xin.
Analysis of the rationality and safety of clinical application of anrotinib in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 329-334.
|
| [15] |
WU Tingxi, ZHAO Zhigang, SHI Yanfeng, ZHANG Yang, ZHANG Yinan, ZHU Bin.
Risk assessment of colchicine-associated neurological adverse events based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 341-345.
|
